INTRODUCTION
============

When Trost and Elliott described the first artificial sphincter in 1947, the external model was largely different from the current model, being controlled by a detachable pump held in the pocket.[@B1] Subsequent modification of the model by Trost and Elliott[@B1] led to the current version of the AUS first implanted by Petero and Diokno[@B2] That model, the AS721, despite being effective, was associated with high rate of complications, failures, and subsequent revision and explantation. To reduce these problems and to further improve the efficacy, newer versions of the American Medical Systems (AMS) artificial urinary sphincter (AUS) were developed until 1983, when the AMS800, the fifth generation of the AMS AUS, was introduced and widely regarded as the AUS of choice for almost 29 years thereafter. Recently, the new Flow Secure AUS was invented, not only to improve the efficacy of the most commonly used AMS800 but also to reduce the complications rate namely urethral atrophy, erosion, and infection, which most of the time required subsequent surgical revision or device explantation.

The AUS consists of three components: the inflatable urethral cuff, the pressure-regulating balloon or reservoir, and the control pump, all of which are connected with tubing systems ([Fig. 1](#F1){ref-type="fig"}). The entire system is filled with fluid, and the device functions using principles of hydraulics. The occlusive cuff provides pressure to maintain continence. The pressure-regulating balloon reservoir regulates the pressure inside the system. During voiding, the fluid inside the cuff is released. This leads to reduction of pressure inside the cuff and allows for the flow of urine. There are various cuff sizes and balloon pressures to adapt to various patient requirements.

The AUS is a complex device. A number of improvements have been made to the device to ease implantation and subsequently reduce the complication, reoperation, and explantation rates. Despite that, the reoperation rate for AUS implantation remains high. There are many medical reasons for the high reoperation, rate but the main reason is still the surgeon\'s experience. Sandhu et al[@B3] concluded that, in contrast to a surgeon\'s typical experience, the learning curve for AUS surgery appears to be very long and without an obvious plateau suggesting a considerable burden of avoidable reoperations.

INDICATION
==========

The AUS was initially implanted primarily in males with urinary incontinence mainly due to radical prostatectomy. The incidence of incontinence after open perineal or retropubic prostatectomy ranges between 0.5 and 40%.[@B4] There is no significant difference in the incidence of post-radical prostatectomy incontinence depending on whether it is done laparoscopically, robotically, or by open operation.[@B5] There is also no difference in the incidence rate based on whether the open radical prostatectomy is performed via a perineal or retropubic approach.[@B5] Currently, there are transitions of indications for implantation of AUS, which include male and female urinary incontinence for various reasons. While post-prostatectomy incontinence remains the main indication for artificial sphincter implantation, there is an increasing trend toward implanting an artificial sphincter for other indications including female urinary incontinence.

AUS implantation should be considered in incontinence secondary to low urethral pressure. Ratan et al[@B6] reported that 90% of AUS implantations were performed in post-prostatectomy patients. The AUS has been considered to be the gold standard for the treatment of post-prostatectomy urinary incontinence. Nowadays, more and more AUS devices have been implanted in incontinence for other causes. The AUS is also indicated in male urinary incontinence secondary to surgery related to benign prostate conditions such as transurethral resection of the prostate (TURP), photoselective vaporization of the prostate (PVP), or holmium laser enucleation of the prostate (HOLEP) and in incontinence after radiation therapy to the prostate. TURP has been associated with a 1\~5% risk of incontinence.[@B7]-[@B10] The incidence of post-PVP incontinence is 0\~6.5%.[@B11]-[@B14] In HOLEP, the reported incidence of incontinence after surgery is 2.2\~7.1%.[@B9],[@B11],[@B15]-[@B17] The reported risk of incontinence in males post-radiotherapy is 0\~18.8%.[@B5] Neuropathic bladder dysfunction with incontinence secondary to intrinsic sphincter deficiency is also an important indication for implantation of an AUS regardless of age and gender.[@B6]

To date, a definitive role for the AUS in adult female urinary incontinence has not been found. Despite that, more and more patients with severe stress urinary incontinence secondary to intrinsic sphincter deficiency have been offered AUS implantation. However, AUS has usually been performed as a last resort after other forms of treatment have failed. Congenital causes of incontinence constitute one of the indications for implantation of an AUS for urinary incontinence in females.[@B18]-[@B20] The other indication for implantation of an AUS in females is incontinence secondary to neurological diseases.[@B2],[@B18]-[@B21]

Orthotopic neobladder has become the standard choice of urinary diversion for cystectomy patients due to the range of diseases, mainly carcinoma of the bladder. Due to the increasing numbers of orthotopic neobladder created, there are also increasing numbers of patients with urinary incontinence, which is one of its known complications. The incidence of incontinence after orthotopic neobladder creation range between 85 and 100% during the day and 55 to 100% during the night.[@B5] Since the first study reported by O\'Connor et al[@B22] regarding the success of the AUS in patients with orthotopic neobladder. there are increasing numbers of AUS devices implanted in patients post-cystectomy with orthotopic neobladder. Infection remains a matter of concern as the orthotopic neobladder is normally colonized with microorganisms but O\'Connor et al[@B22] has reported no increased risk of infection for an AUS implanted in orthotopic neobladder cases.

PREREQUISITES
=============

AUS implantation in males should never be performed until 6\~12 months after the resulting initial event.[@B1] Within this period of time urinary incontinence may improve by itself without intervention. On the other hand, improvement is considered unlikely after this period of time has elapsed. Candidates for AUS implantation should have normal bladder capacity and compliance without any intraurethral or intravesical pathology. Furthermore, such patients should have sufficient physical and mental capacity to deal with the AUS device.

As complications, surgical revisions, and device explantations remain the main concern in AUS implantation, certain measures should be undertaken prior to and during the implantation. The patient should have sterile mid-stream urine before the operation. While in the operation theatre, the patient should undergo a 10 minutes betadine scrub and have the pubic hair shaved. During the operation, waterproof drapes and gowns should be used with the surgeon and assistants wearing double gloves. Antibiotic irrigation should be done during the operation. Hematoma formation should be avoided and post-operative antibiotics should be continued. There should be minimal traffic during the operation.[@B6]

CONTRAINDICATIONS/SPECIAL PRECAUTIONS
=====================================

The AUS is contraindicated in patients with repetitive urinary infection, urethral diverticula at the expected implante site, in complex, unstable, or recurrent urethral stricture diseases, in small capacity and/or non-compliant bladder prior to definitive treatment, in irreversibly obstructed urinary tract or in patients with a lack of physical or mental dexterity to manipulate the pump.[@B23]-[@B27] It is relatively contraindicated in patients with high-grade vesicoureteric reflux, with recurrent intravesical or intraurethral diseases such as stones or tumors, with bladder neck contracture prior to treatment, and with detrusor overactivity.[@B23],[@B25],[@B28]

Radiotherapy-induced incontinence is considered by some scholars to be a contraindication for implantation of the AUS in female patients.[@B18] Thomas et al[@B18] reported a 100% failure rate and considered a history of pelvic radiotherapy as an absolute contraindication to placement of the AUS in women. Vayleux et al[@B29] in their series of women with AUS, confirmed that radiation therapy increases the risk of complications, especially urethral atrophy, cuff erosion, and infection, with subsequent increase in the risk of device failure and revision surgery. However, radiotherapy is not considered to be a contraindication for placement of the AUS in men,[@B30] as the male urethra is longer and the AUS can be implanted around the bulbar urethra. Walsh et al[@B30] reported a similar long-term outcome of AUS in male patients after prostatectomy with or without radiation therapy despite a higher rate of complications in the former. Kim et al[@B31] and Gomha and Boone[@B32] reported that radiation therapy was not associated with an increased risk of AUS complications.

TYPE OF AUS
===========

Currently, the most widely available device is the AMS800 (Amedican Medical System Holdings Inc., Minnetonka, MN, USA) with new devices being released to improve the outcome ([Fig. 1](#F1){ref-type="fig"}).

Petero and Diokno[@B2] created the first AMS device, which was the AS721 ([Fig. 2A](#F2){ref-type="fig"}). Then, the new AMS series was developed, which included the AS742 ([Fig. 2B](#F2){ref-type="fig"}), AS761 ([Fig. 2C](#F2){ref-type="fig"}), AS791/792 ([Fig. 2D](#F2){ref-type="fig"}), and the current most widely used AMS800 ([Fig. 2E, 2F](#F2){ref-type="fig"}). The AS 721, which was the first of the AMS series created, was composed of 4 components connected to each other with valved tubes: the inflatable cuff, the pressure-regulating balloon reservoir, the activating pump, and the deactivating pump. It has the disadvantages of having large numbers of components and tubes, which necessitate extensive dissection with subsequent higher risk of complications and failures. Since then, a great deal of effort has been put into improving the device. The AMS800 is the 5th generation of the AMS series and is now regarded as the gold standard for AUS implantation. The difference between the AMS800 and the AS721 is that the AMS800 incorporates the activating and deactivating pumps into one pump and has kink resistant tubing. Additional refinements include surface treatment, change of shape, such as a narrower back cuff, and color-coded tubes.

Despite all the improvements to the AMS series, the complications and subsequent revision surgery rates are still considered high and further improvement in the outcomes is needed. Therefore, new non-AMS devices have emerged. Vakalopoulos et al[@B33] have come out with the new Flow Secure device, which has the advantage of being a one-piece device. The Flow Secure device, in contrast to the AMS device, is filled with normal saline instead of contrast and cannot be monitored with normal radiological imaging. For that reason, ultrasound is needed for monitoring. In addition, it has two reservoirs among which the stress relief balloon reservoir provides additional pressure to the cuff during increased intraabdominal pressure, thus improving urinary continence.[@B33] The other new device, which has just recently been made available on the market, is the Periurethral Constrictor (Silimed, Rio de Janeiro, Brazil).[@B33] This device is mainly used in pediatric patients. It is a one-piece device with two segments or compartments. It works hydraulically by the injection of sterile solution through the self-sealing valve in order to promote a static occlusive pressure on the cuff. It has the advantages of being simple and cheap. Zephyr surgical implants, a Swiss-French company, has produced a new artificial sphincter device, the ZSI375, designed by Gomez Llorens.[@B33] This device is indicated in stress urinary incontinence secondary to intrinsic sphincter deficiency. It is a one-piece model with two compartments separated by a piston: the hydraulic circuit and the compensation pouch circuit. In addition to the pressure in the hydraulic circuit, the deflated cuff also compresses the urethra, which improves the efficacy and the continence. The ZSI375 has the advantages of increasing the issued pressure and allowing for cuff adjustability. Another new device is the Tape Mechanical Occlusive Device (GU Urological, Minneapolis, MN, USA).[@B33] This is a one-piece device that is manually controlled by the patient through its on and off button. It has two tapes, both of which are connected to the control mechanism: the occlusive tape and the conduit tape.

TYPES OF SURGERY
================

When the AUS was initially introduced, it was mainly implanted via the combined perineal and abdominal approach for male urinary incontinence. As the indications for implantation of the AUS broaden, and as females and children are included, the AUS implantation method now also varies more. The evolution of minimally invasive surgery has had an influence, as the AUS is now being laparoscopically implanted.[@B34]-[@B37] Thus, AUS implantation can be classified into an open or laparoscopic approach.

1. Open method
--------------

1\) The *combined perineal and abdominal approach* is considered the traditional approach for implantation of the AUS in males. The perineal incision is for the implantation of the cuff while the abdominal incision is for the balloon reservoir.

2\) The *trans-scrotal approach* has the advantage of having only a single incision, thus reducing the operation time and shortening the hospital stay. Wilson et al[@B38] has proposed that a single scrotal incision was easier and faster than the traditional two-incision technique. In a patient who has both the problems of incontinence and impotence, a single trans-scrotal incision provides access for the implantation of both the AUS and a penile implant, a device called AMS1500. However, despite the advantages, many experts still believed that the outcome of the trans-scrotal approach is inferior compared to the traditional combined perineal and abdominal approach. It has a lower complete dry rate (27.4% compared to 44.1% in the perineal approach).[@B39]

3\) The *abdominal approach* is mainly used when the intended site for implantation of the AUS is at the bladder neck, especially in females. It is done via the suprapubic approach. It can be challenging, as the AUS for female urinary incontinence is usually a last resort after failure of previous surgeries.

4\) The *combined abdominal and transvaginal approach* can be done for implantation of the AUS in females. Popularized by Appell[@B40] in 1988, this approach mirrors the combined perineal and abdominal approach for males whereby the transvaginal incision is for the insertion of the cuff while the abdominal incision is for the placement of the balloon reservoir. He reported an incredible 100% success rate with this approach.

2\. The *laparoscopic method* of AUS implantation[@B35]-[@B37] is a minimally invasive approach for implantation of the AUS trans-abdominally. It is mainly done for female urinary incontinence. Unlike the open approach, it has the advantage of approaching the site of interest via a virgin area. However, it has a steeper learning curve and requires expertise in laparoscopic skills.

OUTCOMES
========

Many studies have assessed the outcomes of AUS implantation. However, interpretation and direct comparison are difficult due to variability of definitions, surgical techniques, and selection of patients or research populations.

1. Continence rate
------------------

The overall continence rate after implantation of an AUS is 73% and the improved continence rate is 88% in the published literature.[@B41] Venn et al[@B19] reported an 84% continence rate after AUS implantation in both male and female patients at 10 years of follow up. The evolution of new devices has improved the long-term outcomes and reduced the complication rates.

The outcome of AUS implantation differ somewhat in males and females as shown in [Table 1](#T1){ref-type="table"}. In 1983, Barrett and Furlow[@B49] reported a 74% continence rate in AUS implantation for post-prostatectomy incontinence with improvement to 93% when the patients with radiotherapy were excluded. However, this study used an old version of the AUS (AS791). Brito et al,[@B50] with their double cuff technique, improved the continence rate to over 95%. O\'Connor et al,[@B43] however, reported no difference in outcome but higher revision with the double cuff technique. Singh and Thomas[@B42] defined a successful outcome as a \'social continence rate\' (complete continence or minor stress leakage) and reported a 96% continence rate at a mean of 41 months of follow up. Litwiller[@B51] raised the issue of patient satisfaction and exclusively added patient satisfaction in his study. He reported a 97% social continence rate (20% complete continence, 55% a few drops of leakage, 22% less than a teaspoonful of urine/day) at a median follow up of 23.4 months.[@B33] Despite the fact that only 20% achieved complete continence after surgery, 90% of the patients were satisfied with the outcome.[@B51] This shows that patient satisfaction does not necessarily require the patients to be completely dry but rather to experience an improvement in urinary continence. Gousse et al[@B44] took the same approach with Litwiller[@B51] in their study with a mean follow up of 7 years. In contrast to the result reported by Litwiller[@B51], Gousse et al[@B44] reported only 77% patient satisfaction (58% very satisfied, 19% satisfied, and 23% unsatisfied) with the outcome of surgery. The difference between the study by Gousse et al[@B44] and Litwiller et al[@B51] is the duration of the study. Gousse et al[@B44] had a longer study duration. This demonstrates that the longer the duration of AUS in situ, the greater the risk of deterioration, failure, and complications and the lower the patient satisfaction rate.

In comparison to the AUS in males, fewer studies have addressed female urinary incontinence. An earlier review by Venn et al[@B19] showed that outcomes for females were less favorable than for males. However, a later study by Petero and Diokno[@B2] reported no difference in outcomes of AUS in males and females. Costa et al[@B48] has done one of the largest studies concerning AUS in female urinary incontinence of various etiologies. He reported 88.7% and 81.8% continence rates in non-neurogenic and neurogenic causes of urinary incontinence, respectively. Furthermore, the social continence rate was reported as high as 96.4% and 90.9%, respectively.[@B48] On the other hand, Thomas et al,[@B18] who reported an 81% continence rate, had the longest follow-up period of any study we reviewed. Donovan et al[@B21] reported a success rate of 61% from 31 patients, mostly with neuropathic bladders, while Light and Scott[@B52] reported a success of 89% from 39 patients with stress incontinence. Webster et al[@B53] reported a good continence rate of 92% in patients treated with AUS implantation primarily for ISD. However, the continence rate decreased to 60% when the AUS was placed in multiply operated patients,[@B46] which is commonly encountered, as the AUS is normally implanted in females as a last resort after the failure of other methods.

2. Reoperation and explantation rate
------------------------------------

One of the most concerning problems of AUS is the high rate of revision surgery. It has been reported that the overall reoperation rate for AUS implantation is 28\~35%.[@B19],[@B42],[@B54] Venn et al[@B19] reported a 26% reoperation rate, which included both genders. This may be due to technical errors, bladder dysfunction, and mechanical and non-mechanical errors. Once these complications occur, investigations by cystoscopy, and urodynamic and radiological imaging must be performed.

Singh and Thomas[@B42] reported a 36% reoperation rate in their study of post-prostatectomy incontinence. However, following a number of technical improvements of the device, the rate of revision surgery has decreased. Trost and Elliott[@B1] at the Mayo Clinic reported a significant decrease in revision surgery from 42% to 17% following the improvement of the device.[@B42] In males, the explantation rate has been reported to be 16\~20.3%[@B1].

In females, the reoperation rate for AUS ranges from 0 to 80%.[@B29] Furthermore, the explantation rate was in the range of 20\~50% in the literature.[@B29] However, Verlaux et al[@B18] had a lower explantation rate of 7%, which was comparable to the study by Costa et al.[@B48] Venn et al[@B19] stratified their patients by neurogenic and non-neurogenic patients and found that 50% of the female patients with neurogenic causes of incontinence had their AUS explanted in comparison to 30% of male patients. This may be because the AUS cuff is inserted around the female bladder neck, which is a more difficult surgery in comparison to placement of the AUS cuff around the male bulbous urethra.[@B19] Furthermore, the female urethra is thinner than the male bladder neck and AUS implantation is normally performed in females after previous failed attempts at surgery.[@B19]

COMPLICATIONS
=============

AUS implantation is not without untoward complications. Kim et al[@B31] reported an overall complication rate of 37%. Common complications include mechanical failure, urethral erosion, infection, and atrophy leading to recurrent incontinence and subsequently device revision or explantation.

The overall rate of mechanical device failure is 14%.[@B41] This incidence was reduced to 7.6% after the introduction of the narrow-backed cuff device.[@B42],[@B46] Mechanical device failure is estimated to occur in 7.6\~21% of male patients.[@B6],[@B47] Most of the time, it is due to leakage of fluid from the hydraulic system, either from the cuff, the balloon, or the tubing. Total or partial device reimplantation is most likely needed after device failure. Vayleux et al[@B29] reported a 15.3% incidence of device failure in a series of female patients. They identified several risk factors of device failure and subsequent explantation of AUS, including history of radiotherapy, age \>70, and history of previous surgery. However, the body mass index, number of previous operations, parity number or positive Marshall Bonney test were not found to be risk factors in their analysis of the series.

Infection is the most devastating complication and should be avoided by all means. Hajivassiliou[@B41] reported a 4.5% incidence of device infection. The incidence of device infection in adult males is 1\~14%.[@B1] Costa et al[@B20] reported a 4.8% risk of device infection in a series of female patients. Infection necessitates device removal and delayed reimplantation.

Urethral erosion after AUS implantation is a disastrous complication. It can happen early post-operatively or later after convalescence. An overall incidence of delayed erosion of up to 15% for both genders has been reported.[@B46] In males, the incidence has been reported to be 4\~10%.[@B1] In females, Costa et al[@B20] reported a 8.1% incidence of erosion, which includes vagina, labia majora, urethral, and bladder erosion. Once erosion occurs, device removal and delayed reimplantation are almost inevitable. Early urethral erosion happens most commonly due to infection or a technical error during implantation, while delayed urethral erosion occurs due to urethral damage secondary to cuff pressure and improper catheterization.

Urethral atrophy is not infrequent. In males, an incidence rate of 4\~10% has been reported.[@B1] It may result secondary to chronic compression of the urethra. It commonly presents with recurrent incontinence after a period of continence. However, in females, the incidence of urethral atrophy after AUS implantation is not well documented in the literature.

CONCLUSION
==========

The artificial urinary sphincter is safe and effective in management of urinary incontinence in both males and females. While being a gold standard in treating male urinary incontinence, it is also slowly gaining acceptance for female urinary incontinence. Despite being effective with a high satisfaction rate, the pitfall of the AUS remains the high complication, reoperation and explantation rates. Evolution in the design of the device and surgical technique has reduced but not eliminated these problems. Continuous improvement should be done for AUS to make it the method of choice in urinary incontinence of various etiologies.
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